High-Accuracy Differentiation of Lung Adenocarcinoma Identified Through Blood Analysis of 470 Individuals from Five Korean Hospitals

Potential for Recurrence Risk and Prognosis Prediction Confirmed... Expansion Into Targeted Therapies Anticipated

A domestic research team has proposed a potential biomarker that can diagnose early-stage lung adenocarcinoma and even predict the risk of recurrence using small extracellular vesicles (sEV) present in the blood. Through multi-center blood analysis, the study demonstrated a high accuracy in distinguishing between healthy individuals and lung adenocarcinoma patients. Furthermore, the findings suggest that sEVs may be involved in the progression and metastasis of lung cancer, highlighting the possibility of expanding this research into targeted therapies.


From left: Hyungkoo Kim, Department of Cardiovascular and Thoracic Surgery, Korea University Guro Hospital; Byunghyun Choi, Department of Medical Science, Korea University College of Medicine; Hyungjin Ahn, Department of Statistics; Yeonho Choi, Department of Biomedical Engineering, Korea University Guro Hospital.

From left: Hyungkoo Kim, Department of Cardiovascular and Thoracic Surgery, Korea University Guro Hospital; Byunghyun Choi, Department of Medical Science, Korea University College of Medicine; Hyungjin Ahn, Department of Statistics; Yeonho Choi, Department of Biomedical Engineering, Korea University Guro Hospital.

View original image

Korea University Guro Hospital announced on May 22 that a joint research team led by Professor Hyunkoo Kim of the Department of Cardiovascular and Thoracic Surgery confirmed that 'GRIP and coiled-coil domain-containing protein 2 (GCC2)' present in small extracellular vesicles (sEV) in the blood could serve as a diagnostic and prognostic biomarker for early-stage lung adenocarcinoma. The results of this study were recently published in the international journal, the Journal of Extracellular Vesicles.


The research team analyzed plasma samples from a total of 470 individuals—150 healthy controls and 320 patients with lung adenocarcinoma—using clinical data and blood samples collected from five hospitals in Korea: Korea University Guro Hospital, Seoul National University Bundang Hospital, Gangnam Severance Hospital, Asan Medical Center, and Samsung Medical Center.


Extracellular vesicles are nano-sized particles secreted by cells that can reflect the characteristics of cancer cells and the progression of disease, thus garnering attention as biomarkers for liquid biopsy. The research team focused on changes in the concentration of GCC2 protein inside sEVs.


The analysis revealed that the concentration of sEV-GCC2 in the blood of lung adenocarcinoma patients was significantly higher than that of the healthy control group. In particular, sEV-GCC2 distinguished healthy individuals from lung adenocarcinoma patients with high accuracy (AUC 0.904), confirming its potential as a blood-based early diagnostic biomarker.


The possibility of prognostic prediction was also demonstrated. The research team observed that patients with higher preoperative sEV-GCC2 concentrations tended to have an increased risk of recurrence and a shorter recurrence-free survival period. This suggests the potential use of sEV-GCC2 for post-surgical recurrence risk assessment and the development of personalized treatment strategies.


Through additional cell and animal experiments, the team also confirmed that sEV-GCC2 may be involved in cancer cell proliferation, tumor growth, and lymph node metastasis. This indicates that GCC2 could be utilized not only as a diagnostic indicator but also as a target molecule involved in the progression and malignancy of lung cancer.


Professor Hyunkoo Kim stated, "Based on clinical blood samples from multiple hospitals in Korea, we have confirmed the potential of blood-based biomarkers in early-stage lung cancer patients. We expect that this could also assist in pre- and post-surgical risk assessment and in the development of therapeutic strategies for patients going forward."



He added, "Given that we have identified GCC2 as a potential target molecule involved in the progression and malignancy of lung cancer, it is also significant in that it could be expanded into research on GCC2-based targeted therapies for lung cancer in the future."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing